One Stop Target-to-Hit Platform: p53

TP53 is the most frequently mutated tumor suppressor gene in human cancer. Mutant p53 proteins not only lose wild-type p53-dependent tumor suppressive functions, but also frequently acquire oncogenic gain-of-functions that promote tumorigenesis.  Small molecules that can either protect p53 from negative regulators or restore the functionality of mutant p53 proteins are gaining interest, and potential drugs tailored to specific types of p53 mutants are emerging.

To support the discovery of p53-targeted therapeutics, WuXi AppTec offers a comprehensive platform of ready-to-go biophysical assays, high-quality protein production, and established X-ray crystallography protocols.

Target of the month_p53

Download